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Summary A consecutive series of 2,999 patients, diagnosed with Hodgkin's disease (HD) between 1950 and
1979, was assembled from the records of the Birmingham and West Midlands Cancer Registry and followed
to the end of 1984. Cohort analyses of subsequent primary cancers among 1,976 patients, surviving one or
more years (mean follow-up 6.7 person-years), were carried out in relation to overall treatment by
radiotherapy (RT), chemotherapy (CT) or both modalities (CT+RT). Over all sites a 50% increase in risk,
relative to the West Midlands population, was found [observed (0)=65; relative risk (RR)=1.5; P<0.01].
Among patients treated by CT (with or without RT) a significant increase in acute and non-lymphocytic
leukaemias was found (0=6; RR=30.0; P<0.001). The excess risk was of the order of I per 1000 patient-
years and the cumulative risk was 1.2%. Among solid tumours increased risks, which might be attributable to
RT, occurred in the lung (0=15; RR=1.6; P<0.05), breast (O=9; RR=2.2; P<0.05) and bone (0=2;
RR=20.0; P<0.01). The excess of skin cancers (0=13; RR=2.9; P<0.01) occurred mainly within 10 years
of treatment with CT. The follow-up period is still insufficient to determine the long-term effect on the
incidence of solid tumours with long latent periods from multiple-agent CT which became more frequently
used in the early 1970s. A sub-set of these data was analysed over all treatments and the results were
contributed to an international study co-ordinated by the International Agency for Research on Cancer,
Lyon.
Although recent CT regimes have improved the survival rate
in HD, the longer period of remission, together with the
carcinogenic nature of the drugs used to achieve it, have
increased the risk of subsequent primary cancers in those
who respond to treatment.
An early study on second primary cancers in patients
treated for HD between 1953 and 1971 reported a 3-fold
increase in solid tumours. No case of leukaemia was
observed (Arseneau et al., 1972). In the 1970s the use of
combined treatments of RT and CT and of regimens of CT
became more common and by the mid-1980s 29 cases of
acute non-lymphocytic leukaemias developing after treatment
for HD were cited (Greene, 1984). In the same year Boivin
(1984) reviewed 11 studies reporting quantitative estimates of
second primary risks at all sites. The estimates were based
on relative risks in relation to expected risks in the general
population. In a general review of the long-term effects of
therapy in HD (Rowland & Murthy, 1986), the 10-year
actuarial risk of subsequent leukaemias was given as 6-9%
on the basis of 14 reports in the literature, with that for solid
tumours ranging from 2-6%. Increased risks of solid
tumours were not usually found in series with a median
follow-up time of less than 7 years.
Although detailed information on the mode of treatment
was available for the majority of these reports, the numbers
of patients available for comparison have been very small
and this has prevented the clear separation of the effects of
different modalities of treatment on subsequent cancer risk.
By contrast, population-based cancer registries can provide
greater numbers for analysis but are not always able to
distinguish treatment groups.
Among more than 3,000 patients with HD registered
between 1935 and 1982 in Connecticut (Greene & Wilson,
1985) only 97 second primaries were observed, 2 of which
were acute non-lymphocytic leukaemias. However, among
solid tumours, increased risks were observed for buccal
cavity, pharynx and respiratory system in men, and breast
and thyroid in women. The overall risk in the Danish
Cancer Registry material for 1943-1980 was similar to that
of Connecticut but a highly significant excess of acute and
non-lymphocytic leukaemia was observed. Among solid
tumours only respiratory system in men and the bladder in
women appeared to be at increased risk (Storm & Prener,
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1985). Neither registry was able to identify groups treated by
CT, but most of the long-term follow-up refers to patients
treated by RT. A collaborative study, of material from 11
population-based cancer registries co-ordinated at the Inter-
national Agency for Research on Cancer (IARC), was
undertaken to increase the numbers of patients and second
primaries for analysis (Kaldor et al., 1987). The change in
risk over calendar period was examined in order to test the
effect of the introduction of multiple-agent CT. The overall
risk (1.7-fold) was similar to the results from Connecticut
and Denmark. A highly significant excess of acute and non-
lymphocytic leukaemias was observed. The risk increased
with calendar year of diagnosis of HD and remained at a
high level for up to 15 years after treatment.
The present paper reports a follow-up study of all patients
registered at the Birmingham and West Midlands Regional
Cancer Registry between 1950 and 1979 and examines the
incidence of subsequent primary cancers in terms of treat-
ment, interval from first primary and calendar period. The
type of treatment received is routinely recorded at regis-
tration and at follow-up. A sub-set of the data was analysed
and the results were included in the IARC study and
comprised 1950-1976 registrations with follow-up to the end
of 1982. In the present analysis registrations for 1977-1979
have been added and the follow-up for the whole series
extended to the end of 1984.
Materials and methods
A series of 2,999 patients with a diagnosis of HD between
1950 and 1979 was identified from the Registry records. The
age-distribution for 1,826 men and 1,173 women is given in
Table I.
Cancer incidence rates were computed from the Registry
data by site, sex, age and calendar period for all sites and 42
individual sites standardised to the 8th. Revision of the
International Classification of Diseases (ICD8). The numbers
of subsequent cancers that might be expected to occur, on
the basis of no excess risk in the series, were computed by
applying the appropriate incidence rates to the sex-, age- and
calendar period-specific PYR. Subsequent primary cancers
were identified from the Registry data and by scrutiny of the
medical reports at active follow-up.
Two summary indices were used to assess the risk of
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subsequent cancer in the series: relative risk (RR) defined as
the 'observed number/expected number', and an excess mor-
bidity rate (EMR) defined as '(observed-expected number)/
PYR x 103'. The former measures the risk in the series
relative to that in the general population, the latter measures
it on an absolute scale. Significance testing for individual
RRs assumed that the observed numbers followed a Poisson
distribution and exact Poisson probabilities were computed
for a 1-tailed test. Confidence limits for RR and EMR were
computed using Byar's approximation (Rothman & Boice,
1979). Estimates of the cumulative risk of second cancers
(I - P) and comparisons between sub-groups were made by
life-table and log-rank analyses using the methods of Peto et
al. (1976).
Since the main purpose of the study was to examine the
possible effects of treatment on subsequent cancer incidence,
the following tabulations have been restricted to events
occurring 1 or more years after the diagnosis of HD. Thus,
cancers diagnosed at the same time or shortly after HD are
excluded from the analyses.
In the analyses of the leukaemias, A+NLL refers to all
cell-types specified as 'acute' and all other types specified as
'non-lymphocytic', i.e. other leukaemias of the myeloid series.
In general the numbers of second cancers at specific sites
were too small to allow fine division of the data by type and
intensity of treatment or by interval between different types
of treatment. After a preliminary analysis in terms of type of
first treatment and taking into consideration the varying
patterns of order of treatments over the time-period, it was
decided that a more meaningful division could be based on
overall treatment defined in relation to RT and CT. Four
groups were defined as follows:
1. RT: radiotherapy only
2. CT: chemotherapy only
3. RT+CT: radiotherapy and chemotherapy - either con-
current or at intervals
4. OTHER: not covered by 1-3, i.e. not treated, surgery
only, surgery and hormone, hormone only.
Patients in groups 1-3 may also have been treated surgi-
cally with/without hormones.
Results
Follow-up
Of the 2,999 patients in the series, 1,023 (34.1%) died within
the first year. Among 1950-1967 registrations, 38.5% died
within 1 year and 70.4% survived less than 5 years. For
registrations after 1967, the figures were 30.4% and 50.8%
respectively. By the end of the survey 74.2% of all patients
had died; 0.7% were incompletely traced and 0.4% had
emigrated. The total series was observed for 15,506 PYR
(mean =5.2 PYR) and 1-year survivors for 15,187 PYR
(mean=7.7 PYR).
Treatment groups
In the total series 936 patients had received RT of which
Table I Hodgkin's disease: Distribution of all patients by age at
first treatment
Males Females
Age
(years) Number (%) Number (%) Total
<15 80 51 131 (4.4)
15-29 481 332 813 (17.1)
30-44 413 223 636 (21.2)
45-59 447 214 661 (22.0)
60-74 334 257 591 (19.7)
70+ 71 96 167 (5.6)
Total 1,826 (60.9) 1,173 (39.1) 2,999 (100.0)
36.2% were also treated surgically and 7.1% received hor-
mones; 652 received CT (surgery=20.1%, hormone=
59.8%); 947 received CT and RT (surgery=25.2%,
hormone 59.5%). Among the remaining 464, 21.9% were
treated by surgery and 7.5% received hormones. Of the 93
patients in this group who survived more than 1 year, 56
(60%) had been treated surgically (1 with additional hor-
mone), 4 (4.3%) with hormone only. No treatment was given
in 7 cases and for 26 patients the treatment was unknown.
Cancer morbidity - all sites
Among the total series 115 other primary cancers were
diagnosed, of which 42 occurred previous to or co-
incidentally with HD. A further 8 second primaries were
diagnosed in the first year, leaving 65 as the total of
observed cases for analysis in 1,976 patients surviving at
least 1 year for an expectation of 43.04 (RR= 1.5, P<0.01),
over all treatment groups (TabIW II). Although the RRs for
men and women were not significantly different (X2h)=2.01),
the additional excess in women was due mainly to the 2-fold
increase in breast cancers (0=9, RR=2.02; P<0.05). A
moderate excess of non-melanomatous skin cancers was
observed in both men and women. No case of melanoma of
skin occurred. Six cases of A+NLL were diagnosed and the
risk was significantly increased in both men and women
(O=6, RR= 12.5, P<0.001). The combined results for men
and women showed a highly significant excess of bone
cancers (O=2, RR=20.6; P<0.01) and a moderate excess of
lung cancers (O= 15, RR= 1.6; P<0.05). The remainders for
other sites showed relative risks close to 1.0 and no
individual site showed a significant deficit of second
primaries.
For the 3 groups treated by RT or CT, the risk at all sites
was significantly increased to a similar extent. No excess
occurred in the remaining patients (Table III).
Acute and non-lymphocytic leukaemia
No case of chronic lymphatic leukaemia was observed
(E=0.27). For an expectation of 0.48, 6 cases of A+NLL
were diagnosed between 4 and 10 years after the first
treatment for HD. The histologically confirmed cell-types
were acute myeloid (3), acute monocytic (2) and erythro-
leukaemia (1). The results by treatment group and calendar
period are shown in Table IV. The one patient developing a
leukaemia before 1968 had received RT with cyclophos-
phamide and vinblastine as single agents. Acute myeloid
leukaemia was confirmed 10 years later. The remaining 5
cases of leukaemia arose in patients treated after 1968, all of
whom had received multiple-agent CT: 4 patients received
nitrogen mustard, procarbazine and vinblastine (MVPP), 2
of these received additional cyclophosphamide and a third
later RT and vincristine. The fifth patient was treated
initially with RT and vinblastine followed by combination
CT consisting of cyclophosphamide, nitrogen mustard and
procarbazine. All 5 patients had received hormone treatment,
either independently or as part of a polychemotherapeutic
regimen.
Patients treated after 1967 experienced a 20-fold risk
(0=5, E=0.25, RR=20.0, 95% CI 6.4-46.7) of A+NLL,
equivalent in round terms to an EMR of 1 in 1000 PYR
(95% CI 0.2-1.7). No case of A+NLL occurred in the 'RT'
or 'other' treatment groups, although the expected number
(0.11) was comparable with that of the 'CT' and 'CT+RT'
combined (0.14). The apparent differences between CT and
CT+RT for both RR and EMR were not significant.
However, there is no evidence in these results to suggest that
combined modality treatment (CT+RT) incurs a greater risk
of A+NLL than CT alone.
In relation to time since diagnosis of HD, the RR of
A+NLL for the total series was 17.5 (0=6, E=0.34) 10
years after first treatment and 12.5 (0=6, E=0.48) overall.
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Table II Hodgkin's disease: Subsequent primary cancers 1+ years from first primary
Males Females Total
N=1,199 N= 777 N=1,976
Site 0 E OIE 0 E OIE 0 E OIE
All sites (140-208) 36 27.79 1.3 29 15.25 1.9b 65 43.04 1.5
Lung (162) 12 8.30 1.4 3 0.86 3.5 15 9.16 1.6a
Skin (173) 8 3.10 2.6a 5 1.40 3.5a 13 4.50 2.9b
Breast (174) 0 0.04 - 9 4.12 2.2a 9 4.16 2.2a
Leukaemia (A+NLL) 2 0.31 6.3a 4 0.17 24.2c 6 0.48 12.5c
Bone (170) 1 0.07 14.5 1 0.03 33.3a 2 0.10 20.6b
Remainder 13 15.97 0.8 7 8.67 0.8 20 24.64 0.8
N=number of patients entering second year of follow-up; 0=observed number; E=expected number; =P<0.05;
b=p<0.01; c=p<0.001.
Table III Hodgkin's disease: Subsequent primary cancers at all sites by
treatment group
Treatment' N+ 0 E OIE EMR+ + (95% CI)
RT 734 31 20.96 1.5a 1.5 (0.7-2.8)
CT 363 13 7.36 1.8a 3.0 (1.1-6.7)
RT+CT 786 19 10.53 1.8a 2.1 (0.9-4.0)
Other 93 2 4.19 0.5 -
Total 1,976 65 43.03 1.5b 1.7 (1.0-2.5)
+See method for definition of treatment groups.
+ +EMR =(O-E) x 103/PYR.
N+Number of patients surviving at least 1 year.
Table IV Hodgkin's disease: Subsequent acute and non-lymphocytic leukaemias by treatment and calendar period
Year of diagnosis of Hodgkin's disease
1950-1967 1968-1979 Total
Treatment EMR EMR EMR
group 0 E OIE (95% CI) 0 E OIE (95% CI) 0 E OIE (95% CI)
RT 0 0.14 0 0.09 0 0.23 -
CT 0 0.02 - 3 0.06 50.OC 1.9(0.4-5.7) 3 0.08 37.5c 1.6(0.03-4.6)
RT+CT 1 0.04 2S.0 0.6(0.01-3.4) 2 0.08 25.0b 0.8(0.1-2.8) 3 0.12 25.0C 0.7(0.1-2.1)
Other 0 0.03 - - 0 0.02 - 0 0.05
Total 1 0.23 4.3 0.1(0-0.8) 5 0.25 20.0c 0.7(0.2-1.7) 6 0.48 12.5C 0.4(0.1-0.9)
without RT, the overall RR was 29.6 (O=6, E=0.20) and
the EMR 0.97/103 PYR. At 10 years after diagnosis the
corresponding values were 35.5 (0=6, E=0.17) and 1.51/103
PYR.
The cumulative risks by treatment groups are shown in
Table V. Log-rank analyses adjusting for age and sex could
show no differences in risk for treatment (CT vs. CT+RT) or
for calendar period of treatment (<1968 vs. 1968+).
In relation to age at diagnosis the risk of A+NLL was
highly significantly increased in patients under the age of 45
years (0 =5, RR=23.6, P<0.001), only 1 case occurring in
older patients (Table VI). The relative risk for all other
cancers was also significantly increased in the younger age-
group 0=26, RR=2.2, P<0.001) and was significantly
higher than that of older patients (X21=7.19, P<0.01).
Cancers other than A +NLL
When the results for A+NLL had been excluded, a small
excess of cancers at all other sites was observed (0=59,
RR=1.4, P<0.05) (Table VII). Although the RRs were of
Table V Hodgkin's disease: Cumulative risk percent of
A+NLL
Year of Ist treatment
Treatment
group < 1968 1968+ Total
CT 0.0 1.7 1.5
CT+RT 1.6 0.9 1.1
CT+(RT+CT) 1.3 1.2 1.2
the same order for RT/CT treated groups, among those sites
showing an overall increase (see Table II) a highly significant
excess of lung cancers was found in the RT-group (O=11,
RR=2.5, P<0.01) but not in other treatment groups. There
was a 4.3-fold risk of skin cancers in patients treated with
CT, but the risk was also raised (2.3-fold) in the RT-group
and the distribution of the observed cases across treatment
groups was not significantly different from that expected
(X(3)=3.15). The 2-fold risk of breast cancers and the 20-fold
risk of bone cancers are more difficult to attribute to
treatment although both occur in groups treated by RT.
A significant trend for RR over time was found for all
sites excluding A+NLL (X2)=7.31, P<0.01), although the
excess was significant only at 20+ years when 9 cancers were
observed at 6 different sites (Table VIII). These 9 patients
had received RT or combined RT+CT (3 cases) and among
the 6 sites a highly significant trend of increasing relative
risk was observed (X2)=20.69, P<0.01). No trend could be
demonstrated for all other sites (X() = 1.84).
Cancers of the pancreas (2) and ovary (2) were marginally
in excess (P<0.05) in the RT+CT-group but the short
intervals from the diagnosis of HD were not suggestive of a
treatment effect.
Discussion
In this population-based series of patients with HD, diag-
nosed over a long calendar period and treated by varying
therapeutic policies, the risk of subsequent primary cancers
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Table VI Hodgkin's disease: Subsequent cancers in relation to age at 1st treatment
A +NLL All sites (exc.A+NLL)
Age-group
(years) 0 E OIE 0 E OIE
<45 5 0.21 23.6 c 26 11.74 2.2 c
45+ 1 0.27 3.7 - 33 30.82 1.1 -
Total 6 0.48 12.5 c 59 42.56 1.4 a
Table VII Hodgkin's disease: Subsequent primary cancers by treatment group
Treatment group
Site
(ICD 8) RT CT RT+CT Other Total
All sites 0 31 10 16 2 59
(excluding A+NLL) E 20.73 7.29 10.40 4.14 42.56
O/E 1.5 1.4 1.5 0.5 1.4
P a - a
Lung (162) 0 11 2 2 0 15
E 4.48 1.50 2.14 1.03 9.15
O/E 2.5 1.3 0.9 - 1.6
P b - - - a
Skin(173) 0 5 4 4 0 13
E 2.19 0.78 1.08 0.44 4.49
O/E 2.3 5.1 3.7 - 2.9
p - b a c
Breast (174 females) 0 6 1 0 2 9
E 1.94 0.78 1.21 0.19 4.12
O/E 3.1 1.3 - 10.5 2.2
P a a a
Bone (170) 0 1 0 1 0 2
E 0.05 0.01 0.03 0.01 0.10
O/E 20.0 - 33.3 - 20.0
P a a b
Table VIII Hodgkin's disease: Subsequent primary cancers by interval from HD
Year from Ist primary
1-9 10-19 20+
Number entering interval 1,976 570 110
PYR for interval 9,823.6 2,915.5 471.9
P (for
0 E O/E 0 E O/E 0 E O/E trend) Xh)
All sites (excl. A+NLL) 34 29.18 1.2 16 11.02 1.5 9 2.36 3.8 b 7.1
Lung 8 6.25 1.3 4 2.37 1.7 3 0.54 5.6
Breast 3 2.85 1.1 5 1.04 4.8 1 0.23 4.4
Bone 1 0.07 14.3 0 0.02 - 1 0.00 250.0
Oesophagus 1 0.48 2.1 0 0.19 - 1 0.04 25.0
Stomach 1 2.27 0.4 0 0.84 - 2 0.18 11.1
Connective tissue 0 0.17 - 0 0.06 - 1 0.01 100.0
Sub-total 14 12.09 1.2 9 4.52 2.0 9 1.00 9.0 c 20.7
Remainder 20 17.09 1.2 7 6.50 1.1 0 1.36 - 1.8
but no significant difference for relative risks between men
and women could be demonstrated. An attempt was made to
relate this increased risk to the type of overall treatment
given for HD. We found that leukaemias occurred mainly in
patients treated by CT and that solid tumours were asso-
ciated more with RT but for three reasons it is difficult to
attribute the results to direct initiatory effects of treatment at
individual sites: first, some HD patients exhibit pre-treatment
dysfunction of cell-mediated immunity (Twomey & Rice,
1980); second, methods of treatment and survival have
changed over the calendar period, and, third, multiple-agent
CT has been used for a relatively short time in relation to
the long latent periods of solid tumours.
In addition to the pre-treatment deficiency of T-helper cell
lymphocytes, both RT and CT cause further immune
depression. Although some functions rebound to pre-
treatment levels (Rijswijk et al., 1984), the number of T-cell
lymphocytes remains low (Fisher, 1982; Vanhaelen & Fisher,
1982; Hancock et al., 1982) and T-cell helper/suppressor
ratios are reduced (Lauria et al., 1983). It could be, there-
fore, that HD patients are at an increased risk of cancer
because of immune incompetency, a risk which is indepen-
dent of the type of treatment but which could be enhanced
by either RT or CT.
Although CT was used before 1968 (the calendar division
used in the analysis), it consisted mainly of single-agent
therapy given for late presentation or palliation of recurrent
disease. After 1968 more consistent use was made of
multiple-agent cyclical and maintenance therapy. Despite the
high mortality in pre-1968 cases- around 70% at 5 years -
the numbers of subsequent cancers (excluding A+NLL)
expected in this group are similar for 1-9 years and 10+
years after HD but the survivors at 10+ years had been
treated mainly by RT. Thus, the 2-fold risk at this time is516 P. PRIOR & D.J. POPE
more likely to arise from the effect of RT than CT. The
apparent association with RT could, however, be an artefact
of survival in that the majority of 10-year survivors have
received RT, although the sites found to be at long-term
increased risk - lung, breast, stomach and oesophagus -
were likely to be within the treatment fields.
By contrast, what little excess is seen in the post-1968
cases (after the exclusion of A+NLL) occurred in the CT-
group (0=10, E=4.87, P<0.05) and, during years 1-9, in
all patients receiving CT either alone or in combination
(0=17, E= 10.46, P<0.05). With an expected number of
only 2.62 for 10+ years there has as yet been insufficient
follow-up to demonstrate initiatory effects of CT for solid
tumours. Since this lack of long-term follow-up after multi-
modular treatment is common to most studies, it may
explain Rowland's observation (Rowland & Murthy, 1986)
that solid tumours have consistently developed in patients
treated by RT alone. However, the small increase within the
first 10 years of follow-up might be indicative of an acceler-
ation of cancers initiated prior to treatment for HD as a
result of the depressed immune status. An early increased
risk of skin cancers and lymphomas has been reported in
immune-suppressed patients following organ transplants
(Kinlen et al., 1979).
The Birmingham series formed 10% of cases in the IARC
study (Kaldor et al., 1987) and in general our findings were
consistent with the larger study. The overall risk in the
Birmingham series for all subsequent cancers was lower but
not significantly so (1.8 vs. 1.5, X(1)= 1.6), the difference
being more marked in men (1.8 vs. 1.3, X()=3.92, P<0.05)
but not in women (1.7 vs. 1.9, X%)=0.13). The overall
relative risk was also very similar to that reported by the
Thames Cancer Registry (0=58, E=41.78, RR= 1.4,
P<0.05) (Coleman et al., 1987).
In our series the overall relative risk of A+NLL
(RR= 12.5; 95% CI=5-27) was somewhat lower than in
the IARC study (RR= 16.9), but not significantly so
(X2)=0.30). In the latter study the risk for 1970+ regis-
trations (RR=24.1) was comparable with our figure of 20.0
(95% CI=6-47) for 1968+ registrations. The larger study
showed a continuing risk of A+NLL 10 years or more after
diagnosis of HD, whereas we observed no case after 10 years
during which period the expected number of 0.14 was
probably too small to detect the 13-fold relative risk shown
in the IARC series.
With respect to sites of solid tumours the relative risks for
lung (1.6), breast (2.2) and non-melanomatous skin (2.9)
were not significantly different from those in the IARC
study which were respectively 1.9, 1.4 and 2.2 (X2)=0.22'
1.03, 0.66). Both studies showed an excess of bone cancers
but the numbers were too small to make a satisfactory
comparison. Sites which also showed significant excesses in
the larger study included salivary gland, nasopharynx, skin
melanoma and larynx. At the risk levels quoted for these
sites, our smaller study would be unable to detect an
increase because the anticipated observed number would be
less than 1. We found no excess of cervical cancer (O= 1,
E= 1.2) although a 2-fold risk was found over all registries.
Although the excess of non-Hodgkin's lymphoma in our
series did not achieve statistical significance (0=2, E=0.68,
RR =2.9), the relative risk was of the same order as that of
the IARC study (O= 15, RR= 3.0).
Four of the 5 sites of cancer reported in the IARC study
as 'likely' to be treatment-related - leukaemia, lung, breast
and skin - were also detected in our series, as was bone
cancer among the three sites reported as 'possibly' treatment-
related. For cancers of salivary gland, thyroid (possibly
related) and non-Hodgkin's lymphoma (likely to be related)
the expected numbers generated from our data were pro-
bably too small to detect the levels of risk found in the
larger study. There was also some evidence for increasing
risks over time for stomach cancer in men and for bladder
cancer in the IARC series. Stomach was among the six sites
for which cancers were observed at 20+ years in our series,
but the reported levels of risk were not high and, again,
small numbers at risk may account for our failure to detect
an effect, although differences in treatment practices might
also be responsible for variations between series.
The increased risk of leukaemia in our series is consistent
with previous reports from clinical series: the risk occurs in
patients treated by CT but not in those receiving radical RT
(Valagussa et al., 1982; Henry-Amar, 1983; Papa et al., 1984;
Boivin et al., 1984; Tucker et al., 1987). The measurement of
risk has been presented in varying ways in the literature: (i)
risk relative to that in the general population, (ii) actuarial
risk or (iii) a crude rate in terms of total patient-years at
risk. In comparing the results from different studies,
problems arise because, in general, the number of leukaemias
in each study is small and further division into treatment
groups leads to very wide confidence limits for the risk
estimates. In addition varying definitions of 'intensive'
therapy have been used.
The wide range in reported relative risk - 29-fold to 89-
fold - may result from variations in stage, type of treatment
and age (Henry-Amar, 1983; Boivin et al., 1984; Tucker et
al., 1987). Among 6 clinical series (Canellos et al., 1975;
Toland et al., 1978; Coleman et al., 1982; Henry-Amar,
1983; Boivin & Hutchison, 1984; Tucker et al., 1987) the
absolute risk of leukaemia varied from 1.0 to 8.3/103 PYR
with a mean of 2.0 (95% CI= 1.5-2.6). The rate in the
present series was 0.5/103 PYR overall and 1/103 PYR for
those treated after 1967. The cumulative risk of leukaemia in
our series among patients receiving any CT was 1.2% and is
also low compared with other reports: 1.2%-15% (Tester et
al., 1984). These differences may be due to the unselected
nature of our series, a smaller percentage of patients receiv-
ing intensive CT, or to a low rate of staging laparotomy
with splenectomy. A strong association between splenectomy
and leukaemia has been reported (Van Leeuwen et al., 1987),
and, although the overall rate of splenectomy in our series
was not ascertained, 2 out of 6 leukaemia cases and only 2
out of 59 patients with other cancers had undergone a
splenectomy. The findings in our study are consistent with
previous reports (Boivin et al., 1984; Tucker et al., 1987), in
that the 6 patients with leukaemia had received at least one
alkylating agent and that the risk of leukaemia was not
increased in those receiving only RT.
The results of our analyses are, therefore, broadly consis-
tent with both the larger combined registry study and with
the smaller clinical studies, and they demonstrate the capa-
bility of routinely collected registry data to detect subsequent
risks in the context of a local population. Although the
attribution of risk to individual treatment policies is not
always clear, such studies point to areas for more detailed
research on dose-response effects which may identify the
specific agents involved. The elevated risk of second primary
cancers in long-term survivors of HD suggests that surveil-
lance should continue in recurrence-free patients
This study was supported by the Cancer Research Campaign.
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